Yahoo Web Search

Search results

1. • 

     Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial

     MedPage Today· 3 days ago

     Replacing chemotherapy with a targeted agent resulted in a better tolerated regimen for advanced...

2. • 

     After Losing More Than an Inch in Height, a Shocking New Diagnosis Changed My Life

     Prevention· 2 days ago

     Prior to my diagnosis, I was (and still am) a patient at Dana Farber Cancer Institute in the Adult...

3. • 

     Teen to embark on solo flight around the world to raise money for cancer research

     WFMZ Eastern Pennsylvania and Western New Jersey· 4 days ago

     If he completes the attempt, he'll be the youngest person to ever fly solo across all seven...

4. • 

     ...Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in...

     KOIN News 6 Portland· 17 hours ago

     ...biopharmaceutical company that develops, manufactures and commercializes high-quality medicines...

5. • 

     Obituaries in Waynesboro, PA | The RecordHerald

     The Waynesboro Record Herald· 6 days ago

     Steven Andrew “Andy” Perrin, 49, Boswell, passed away on May 25, 2024 surrounded by his closest family members and friends. Preceded in death by his...

6. • 

     Cancer Survivors Are Sharing The Weird Symptom That Made Them Go "Hm, Something Isn't Right Here,"...

     BuzzFeed via Yahoo News· 2 days ago

     "If they tell you it might be cancer and have you come back in a couple of weeks for a biopsy, say...

7. • BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's...

     Digital Journal· 4 days ago

     LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,

8. • Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...

     Morningstar· 1 day ago

     Gilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...

9. • 

     Raleigh facility plays key role in $245M collaboration - Triangle Business Journal

     The Business Journals· 4 days ago

     A biotech manufacturing facility in Raleigh is a key part of a collaboration between global...

10. • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 19 hours ago

      -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 ...